Synergistic Association of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 on the Risk of Abnormal Glucose Regulation

References

• GBD. 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171. doi:10.1016/S0140-6736(14)61682-2
   PubMed Web of Science ®Google Scholar
• Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281. doi:10.1016/j.diabres.2018.02.023
   PubMed Web of Science ®Google Scholar
• Sheen YJ, Hsu CC, Jiang YD, Huang CN, Liu JS, Sheu WH. Trends in prevalence and incidence of diabetes mellitus from 2005 to 2014 in Taiwan. J Formos Med Assoc. 2019;118(Suppl 2):S66–S73. doi:10.1016/j.jfma.2019.06.016
   PubMedGoogle Scholar
• Porta M, Curletto G, Cipullo D, et al. Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence. Diabetes Care. 2014;37(6):1668–1674. doi:10.2337/dc13-2101
   PubMed Web of Science ®Google Scholar
• Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract. 2014;103(2):150–160. doi:10.1016/j.diabres.2013.11.001
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S13–S28. doi:10.2337/dc19-S002
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.
   PubMed Web of Science ®Google Scholar
• Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–5327. doi:10.1200/JCO.2006.08.2644
   PubMed Web of Science ®Google Scholar
• Touitou Y, Proust J, Klinger E, Nakache JP, Huard D, Sachet A. Cumulative effects of age and pathology on plasma carcinoembryonic antigen in an unselected elderly population. Eur J Cancer Clin Oncol. 1984;20(3):369–374. doi:10.1016/0277-5379(84)90083-X
   PubMedGoogle Scholar
• Amino N, Kuro R, Yabu Y, et al. Elevated levels of circulating carcinoembryonic antigen in hypothyroidism. J Clin Endocrinol Metab. 1981;52(3):457–462. doi:10.1210/jcem-52-3-457
   PubMedGoogle Scholar
• Ruibal Morell A. CEA serum levels in non-neoplastic disease. Int J Biol Markers. 1992;7(3):160–166. doi:10.1177/172460089200700307
   PubMedGoogle Scholar
• Tong HL, Dong ZN, Wen XY, Gao J, Wang B, Tian YP. Impact of chronic kidney disease on serum tumor markers concentrations. Chin Med J. 2013;126(2):274–279.
   PubMed Web of Science ®Google Scholar
• Pines E, Slama JL, Holeman A, Ley G, Malbec D, Boudon P. Taux inhabituellement élevé du CA 19-9 au cours d’une pancréatite chronique [Unusually high level of CA 19-9 in chronic pancreatitis]. Gastroenterol Clin Biol. 1995;19(6–7):641–642.
   PubMedGoogle Scholar
• Mukae H, Hirota M, Kohno S, et al. Elevation of tumor-associated carbohydrate antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis. 1993;148(3):744–751. doi:10.1164/ajrccm/148.3.744
   PubMedGoogle Scholar
• Fukuda I, Yamakado M, Kiyose H. Influence of smoking on serum carcinoembryonic antigen levels in subjects who underwent multiphasic health testing and services. J Med Syst. 1998;22(2):89–93. doi:10.1023/A:1022643102208
   PubMedGoogle Scholar
• Bilge Ü, AN YG, Gölge N, Kara B. Relationship of CA 19-9 with choledocholithiasis and cholangitis. Turk J Gastroenterol. 2011;22(2):171–177. doi:10.4318/tjg.2011.0186
   PubMedGoogle Scholar
• Shively JE, Beatty JD. CEA-related antigens: molecular biology and clinical significance. Crit Rev Oncol Hematol. 1985;2(4):355–399. doi:10.1016/S1040-8428(85)80008-1
   PubMedGoogle Scholar
• Kannagi R. Carbohydrate antigen sialyl Lewis a–its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J. 2007;30(3):189–209.
   PubMedGoogle Scholar
• Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell. 1989;57(2):327–334. doi:10.1016/0092-8674(89)90970-7
   PubMed Web of Science ®Google Scholar
• Berg EL, Robinson MK, Mansson O, Butcher EC, Magnani JL. A carbohydrate domain common to both sialyl Le(a) and sialyl Le(X) is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1. J Biol Chem. 1991;266(23):14869–14872.
   PubMed Web of Science ®Google Scholar
• Bagaria B, Sood S, Sharma R, Lalwani S. Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis). Cancer Biol Med. 2013;10(3):148–157. doi:10.7497/j.issn.2095-3941.2013.03.005
   PubMedGoogle Scholar
• Shibutani M, Maeda K, Nagahara H, et al. Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer. Anticancer Res. 2014;34(7):3753–3758.
   PubMed Web of Science ®Google Scholar
• Shimojo N, Naka K, Nakajima C, et al. The effect of non-insulin-dependent diabetes on serum concentrations of tumor-associated carbohydrate antigens of CA19-9, CA-50, and sialyl SSEA-1 in association with the Lewis blood phenotype. Clin Chim Acta. 1990;190(3):283–289. doi:10.1016/0009-8981(90)90182-R
   PubMedGoogle Scholar
• Petit JM, Vaillant G, Olsson NO, et al. Elevated serum CA19-9 levels in poorly controlled diabetic patients. Relationship with Lewis blood group. Gastroenterol Clin Biol. 1994;18(1):17–20.
   PubMedGoogle Scholar
• Uygur-Bayramicli O, Dabak R, Orbay E, et al. Type 2 diabetes mellitus and CA 19-9 levels. World J Gastroenterol. 2007;13(40):5357–5359. doi:10.3748/wjg.v13.i40.5357
   PubMedGoogle Scholar
• Nakamura N, Aoji O, Yoshikawa T, et al. Elevated serum CA19-9 levels in poorly controlled diabetic patients. Jpn J Med. 1986;25(3):278–280. doi:10.2169/internalmedicine1962.25.278
   PubMedGoogle Scholar
• Yu H, Li R, Zhang L, Chen H, Bao Y, Jia W. Serum CA19-9 level associated with metabolic control and pancreatic beta cell function in diabetic patients. Exp Diabetes Res. 2012;2012:745189. doi:10.1155/2012/745189
   PubMedGoogle Scholar
• Murai J, Soga S, Saito H, et al. Study on the mechanism causing elevation of serum CA19-9 levels in diabetic patients. Endocr J. 2013;60(7):885–891. doi:10.1507/endocrj.EJ12-0364
   PubMedGoogle Scholar
• Gul K, Nas S, Ozdemir D, Gumus M, Ersoy R, Cakir B. CA 19-9 level in patients with type 2 diabetes mellitus and its relation to the metabolic control and microvascular complications. Am J Med Sci. 2011;341(1):28–32. doi:10.1097/MAJ.0b013e3181f0e2a0
   PubMed Web of Science ®Google Scholar
• Huang Y, Xu Y, Bi Y, et al. Relationship between CA 19-9 levels and glucose regulation in a middle-aged and elderly Chinese population. J Diabetes. 2012;4(2):147–152. doi:10.1111/j.1753-0407.2011.00179.x
   PubMed Web of Science ®Google Scholar
• Esteghamati A, Hafezi-Nejad N, Zandieh A, Sheikhbahaei S, Emamzadeh-Fard S, Nakhjavani M. CA 19-9 is associated with poor glycemic control in diabetic patients: role of insulin resistance. Clin Lab. 2014;60(3):441–447. doi:10.7754/Clin.Lab.2013.121243
   PubMedGoogle Scholar
• Tu Y, Yu H, Zhang P, et al. Decreased serum CA19-9 is associated with improvement of insulin resistance and metabolic control in patients with obesity and type 2 diabetes after Roux-en-Y gastric bypass. J Diabetes Investig. 2014;5(6):694–700. doi:10.1111/jdi.12200
   PubMed Web of Science ®Google Scholar
• Benhamou PY, Vuillez JP, Halimi S, Meffre G, Bachelot I. Influence of metabolic disturbances of diabetes mellitus on serum CA 19-9 tumor marker. Diabete Metab. 1991;17(1):39–43.
   PubMedGoogle Scholar
• Hasan M, Mohieldein A. Association between serum carcinoembryonic antigen level and oxidative stress parameters among diabetic females. Int J Clin Exp Med. 2015;8(4):6489–6494.
   PubMed Web of Science ®Google Scholar
• Ata N, Dal K, Kucukazman M, et al. The effect of glycemic control on CEA, CA 19-9, amylase and lipase levels. Open Med. 2014;10(1):8–13. doi:10.1515/med-2015-0002
   Google Scholar
• Zayed AA, Beano AM, Amer FN, et al. Serum levels of carcinoembryonic antigen in patients with type 2 diabetes. Endocr Pract. 2016;22(11):1310–1318. doi:10.4158/EP161221.OR
   PubMed Web of Science ®Google Scholar
• Shang X, Song C, Du X, Shao H, Xu D, Wang X. The serum levels of tumor marker CA19-9, CEA, CA72-4, and NSE in type 2 diabetes without malignancy and the relations to the metabolic control. Saudi Med J. 2017;38(2):204–208. doi:10.15537/smj.2017.2.15649
   PubMed Web of Science ®Google Scholar
• Lu J, Wang H, Zhang X, Yu X. HbA1c is positively associated with serum carcinoembryonic antigen (CEA) in patients with diabetes: a cross-sectional study. Diabetes Ther. 2018;9(1):209–217. doi:10.1007/s13300-017-0356-2
   PubMedGoogle Scholar
• Chung S, Lee Y, Roh EY. HbA1c showed a positive association with carcinoembryonic antigen (CEA) level in only diabetes, not prediabetic or normal individuals. J Clin Lab Anal. 2019;33(6):e22900. doi:10.1002/jcla.22900
   PubMed Web of Science ®Google Scholar
• Esteghamati A, Zandieh A, Saadipoor A, et al. The role of metabolic syndrome and related clinical variables in determining CEA levels. Adv Clin Exp Med. 2014;23(6):907–912. doi:10.17219/acem/37334
   PubMedGoogle Scholar
• Guo Q, Kang M, Zhang B, Chen Y, Dong X, Wu Y. Elevated levels of CA 19-9 and CEA in pancreatic cancer-associated diabetes. J Cancer Res Clin Oncol. 2010;136(11):1627–1631. doi:10.1007/s00432-010-0820-0
   PubMedGoogle Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–S266.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735–2752. doi:10.1161/CIRCULATIONAHA.105.169404
   PubMed Web of Science ®Google Scholar
• Okumura M, Yamamoto M, Sakuma H, et al. Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-α and PPAR expression. Biochim Biophys Acta. 2002;1592(2):107–116. doi:10.1016/S0167-4889(02)00276-8
   PubMed Web of Science ®Google Scholar
• Liu H, Ma Q, Li J. High glucose promotes cell proliferation and enhances GDNF and RET expression in pancreatic cancer cells. Mol Cell Biochem. 2011;347(1–2):95–101. doi:10.1007/s11010-010-0617-0
   PubMedGoogle Scholar
• Nunez NP, Oh WJ, Rozenberg J, et al. Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Res. 2006;66(10):5469–5476. doi:10.1158/0008-5472.CAN-05-4102
   PubMed Web of Science ®Google Scholar
• Stattin P, Björ O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007;30(3):561–567. doi:10.2337/dc06-0922
   PubMed Web of Science ®Google Scholar
• Yang X, Ko GT, So WY, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes. 2010;59(5):1254–1260. doi:10.2337/db09-1371
   PubMedGoogle Scholar
• Goto A, Noto H, Noda M, et al. Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) joint committee on diabetes and cancer, second report. Diabetol Int. 2016;7(1):12–15. doi:10.1007/s13340-016-0257-z
   PubMedGoogle Scholar
• Bessa X, Elizalde JI, Mitjans F, et al. Leukocyte recruitment in colon cancer: role of cell adhesion molecules, nitric oxide, and transforming growth factor β1. Gastroenterology. 2002;122(4):1122–1132. doi:10.1053/gast.2002.32369
   PubMedGoogle Scholar
• Pham MN, Hawa MI, Roden M, et al. Increased serum concentrations of adhesion molecules but not of chemokines in patients with Type 2 diabetes compared with patients with Type 1 diabetes and latent autoimmune diabetes in adult age: action LADA 5. Diabet Med. 2012;29(4):470–478. doi:10.1111/j.1464-5491.2011.03546.x
   PubMedGoogle Scholar
• Pham MN, Hawa MI, Pfleger C, et al. Pro-and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: action LADA 4. Diabetologia. 2011;54(7):1630–1638. doi:10.1007/s00125-011-2088-6
   PubMed Web of Science ®Google Scholar
• Xiang Y, Zhou P, Li X, et al. Heterogeneity of altered cytokine levels across the clinical spectrum of diabetes in China. Diabetes Care. 2011;34(7):1639–1641. doi:10.2337/dc11-0039
   PubMedGoogle Scholar
• Salman ZK, Refaat R, Selima E, El Sarha A, Ismail MA. The combined effect of metformin and L-cysteine on inflammation, oxidative stress and insulin resistance in streptozotocin-induced type 2 diabetes in rats. Eur J Pharmacol. 2013;714(1–3):448–455. doi:10.1016/j.ejphar.2013.07.002
   PubMed Web of Science ®Google Scholar
• Stern N, Markel G, Arnon TI, et al. Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J Immunol. 2005;174(11):6692–6701. doi:10.4049/jimmunol.174.11.6692
   PubMed Web of Science ®Google Scholar
• Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915–928. doi:10.1038/nrc2536
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–1685. doi:10.2337/dc10-0666
   PubMed Web of Science ®Google Scholar
• Williams JA, Goldfine ID. The insulin-pancreatic acinar axis. Diabetes. 1985;34(10):980–986.
   PubMed Web of Science ®Google Scholar
• Wajchenberg BL. β-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28(2):187–218. doi:10.1210/10.1210/er.2006-0038
   PubMed Web of Science ®Google Scholar
• Prentki M. Islet beta cell failure in type 2 diabetes. J Clin Invest. 2006;116(7):1802–1812. doi:10.1172/JCI29103
   PubMed Web of Science ®Google Scholar
• Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes. 2003;52(1):1–8. doi:10.2337/diabetes.52.1.1
   PubMed Web of Science ®Google Scholar
• Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76–79. doi:10.1001/jama.289.1.76
   PubMed Web of Science ®Google Scholar
• Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med. 1991;325(3):147–152. doi:10.1056/NEJM199107183250302
   PubMed Web of Science ®Google Scholar
• Nguyen NT, Nguyen XM, Lane J, Wang P. Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999-2006. Obes Surg. 2011;21(3):351–355. doi:10.1007/s11695-010-0335-4
   PubMedGoogle Scholar
• Hayashi T, Tsumura K, Suematsu C, Endo G, Fujii S, Okada K. High normal blood pressure, hypertension, and the risk of type 2 diabetes in Japanese men. The Osaka Health Survey. Diabetes Care. 1999;22(10):1683–1687. doi:10.2337/diacare.22.10.1683
   PubMedGoogle Scholar
• U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care. 1997;20(11):1683–1687. doi:10.2337/diacare.20.11.1683
   PubMedGoogle Scholar
• Rooney MR, Pankow JS, Sibley SD, et al. Serum calcium and incident type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Am J Clin Nutr. 2016;104:1023–1029. doi:10.3945/ajcn.115.130021
   PubMedGoogle Scholar
• Xuan Y, Zhao HY, Liu JM. Vitamin D and type 2 diabetes mellitus (D2). J Diabetes. 2013;5(3):261–267. doi:10.1111/1753-0407.12024
   PubMedGoogle Scholar
• Mitri J, Pittas AG. Vitamin D and diabetes. Endocrinol Metab Clin North Am. 2014;43(1):205–232. doi:10.1016/j.ecl.2013.09.010
   PubMed Web of Science ®Google Scholar
• Reis JP, Michos ED, Selvin E, Pankow JS, Lutsey PL. Race, vitamin D-binding protein gene polymorphisms, 25-hydroxyvitamin D, and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Am J Clin Nutr. 2015;101(6):1232–1240. doi:10.3945/ajcn.115.107334
   PubMedGoogle Scholar